Quantcast

Latest Oncotype DX Stories

2014-08-08 08:26:06

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34(th) Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET). http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-07-31 08:35:54

REDWOOD CITY, Calif., July 31, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 7 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of the second quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on...

2014-06-16 12:29:09

Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx(TM) Portfolio CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, today announced its laboratory, located in Cambridge, MA, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services' Centers for...

2014-06-11 08:29:34

Complete Data to be Submitted for Presentation at the 2014 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary...

2014-06-04 15:29:19

Albert Einstein College of Medicine The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI). "Tests assessing metastatic risk can help doctors identify which patients should receive aggressive therapy and which patients should be spared,"...

2014-06-03 16:24:50

BRONX, N.Y., June 3, 2014 /PRNewswire-USNewswire/ -- A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread, or metastasis, for the most common type of breast cancer. http://photos.prnewswire.com/prnvar/20140603/93895 The study was led by researchers at the National Cancer Institute (NCI)?designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and...

2014-06-03 08:32:24

Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX(®) test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related